重度慢性阻塞性肺疾病治疗中噻托溴铵运用.docVIP

重度慢性阻塞性肺疾病治疗中噻托溴铵运用 　　[摘要] 目的 分析探?噻托溴铵治疗重度慢性阻塞性肺疾病的临床疗效和安全性。 方法 随机将方便选取的该院2016年3月―2017年2月收治的76例重度慢性阻塞性肺疾病患者分为观察组和对照组，各38例，对照组给予常规治疗，观察组在对照组的基础上给予噻托溴铵干粉吸入治疗。观察两组患者用药前、用药4周、用药12周的各项肺部评分。 结果 观察组治疗后4、12周的呼吸困难评分分别为（2.34±0.65）分、（1.76±0.54）分均较治疗前（2.82±0.58）分有所降低，且差异有统计学意义（P0.05）。 结论 噻托溴铵是治疗重度慢性阻塞性肺疾病患者的理想用药，值得临床推广应用。 　　[关键词] 噻托溴铵；慢性阻塞性肺疾病；呼吸困难评分；肺功能 　　[中图分类号] R563 [文献标识码] A [文章编号] 1674-0742（2017）09（c）-0146-03 　　Application of Tiotropium Bromide in Treatment of Severe Chronic Obstructive Pulmonary Disease 　　YANG Ming-juan 　　Department of Respiration， Inner Mongolia Forestry General Hospital Second Clinical Medical College of Inner Mongolia University for the Nationalities， Yakeshi， Inner Mongolia， 022150 China 　　[Abstract] Objective To analyze and study the clinical curative effect and safety of tiotropium bromide in treatment of severe chronic obstructive pulmonary disease. Methods 76 cases of patients with severe chronic obstructive pulmonary disease admitted and treated in our hospital from March 2016 to February 2017 were conveniently selected and divided into two groups with 38 cases in each， the control group adopted the routine treatment， while the observation group adopted the dry powder inhalation of tiotropium bromide on the basis of the control group， and various lung scores of the two groups before medication， at 4-week and 12-week medication were observed. Results The dyspnea scores at 4-week and 12-week treatment in the observation group decreased compared with those before treatment[（2.34±0.65）points，（1.76±0.54）points vs （2.82±0.58）points]， and the difference was obvious（P0.05）. Conclusion The tiotropium bromide is an ideal drug in treatment of severe chronic obstructive pulmonary disease， which is worth promotion and application. 　　[Key words] Tiotropium bromide； Chronic obstructive pulmonary disease； Dyspnea score； Lung function 　　慢性阻塞性肺疾病（COPD）是一种常见的以持续气流受限为特征的可以预防和治疗的疾病，是一种具有气流阻塞特征的慢性支气管炎和（或）肺气肿，可进一步发展为肺心病和呼吸衰竭的常见慢性疾病。与有害气体及有害颗粒的异常炎症反应有关，致残率和病